Theiler's virus encephalomyelitis infection as a model for multiple sclerosis: Cytokines and pathogenic mechanisms;Encefalomielitis por infección con el virus de Theiler como modelo experimental de esclerosis múltiple: Citocinas y posibles mecanismos patogénicos

Revista de Neurologia

Volumn 35, Issue 10, 2002, Pages 973-978

  Molina Holgado, E ^a   Arevalo Martin A ^a   Vela, J M ^a   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

Cytokines; Multiple sclerosis; Theiler's virus

Indexed keywords

CYTOKINE; EPITOPE;

CELLULAR IMMUNITY; DEMYELINATING DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PARALYSIS; REVIEW; T LYMPHOCYTE; VIRUS INFECTION;

EID: 0037121399     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3510.2002377     Document Type: Review

References (51)

1. Kurtze JF. Epidemiological evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993; 6: 382-98.
2. Dal Canto MC, Lipton HL. Primary demyelination in Theiler's virus infection. Lab Invest 1976; 33: 626-37.
3. Hertzler S, Luo M, Lipton HL. Mutation of predicted virion pit residues alters binding of Theiler's virus to BHK-21 cells. J Virol 2000; 74: 1994-2004.
4. Lipton HL, Kratochvil J, Sethi P, Dal Canto MC. Theiler's virus antigen detected in mouse spinal cord 2 1/2 years after infection. Neurology 1986; 34: 1117-9.
5. Clatch RJ, Lipton HL, Miller SD. Characterization of Theilers' murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: Correlations with clinical signs. J Immunol 1986; 136: 920-7.
6. Monteney P, Bureau JF, Brahic M. The infection of mouse by Theiler's virus: From genetics to immunology. Immunol Rev 1997; 159: 163-75.
7. Brahic M, Bureau JF. Genetics of susceptibility to Theiler's virus infection. Bioassays 1998; 20: 627-35.
8. Lledó A, Borrell J, Guaza C. Dexamethasone regulation of interleukin-1 receptors in the hippocampus of Theiler's virus-infected mice: Effects on virus mediated demyelination. Eur J Pharmacol 1999; 372: 75-83.
9. Tsunoda I, Fujinami RS. Two models for multiple sclerosis: Experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J Neuropathol Exp Neurol 1996; 55: 673-86.
10. Rodriguez M, Pavelko KD, Njenga MK, Logan WC, Wettstein PJ. The balance between persistent virus infection and immune cells determines demyelination. J Immunol 1996; 157: 5699-709.
11. +T cell-mediated pathology. J Immunol 1996; 156: 4050-8.
12. Miller SD, Vanderlugt CL, Begolka WS, Pao R, Yauth L, Neville KL, et al. Persistent infection with Theiler's virus lead to autoimmunity via epitope spreading. Nat Med 1997; 3: 1133-6.
13. Katz-Levy Y, Neville KL, Padilla J, Rahbe S, Begolka WS, Girvin AM, et al. Temporal development of autoreactive Th1 responses and endogenous presentation of self myelin epitopes by central nervous system-resident APC in Theiler's virus-infected mice. J Immunol 2000; 165: 5304-14.
14. Molina-Holgado E, Vela JM, Arévalo-Martín A, Guaza C. LPS/IFN-γ cytotoxicity in oligodendroglial cells. Role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. Eur J Neurosci 2001; 13: 492-503.
15. Bright JJ, Musuro BF, Sriram S. Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J Neuroimmunol 1998; 82: 22-30.
16. Inoue A, Koh CS, Yamazaki M, Yahikozawa H, Ichikawa M, Yagita H, et al. Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. J Immunol 1998; 194: 186-93.
17. Bright JJ, Rodríguez M, Sriram S. Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced central nervous system demyelination. J Virol 1999; 73: 1637-9.
18. Sato S, Reiner SL, Jensen MA, Roos RP. Central nervous system mRNA expression following Theiler's murine encephalomyelitis virus infection. J Neuroimmunol 1996; 76: 213-32.
19. Murray PD, Krivacic K, Chernosky A, Ransohoff RM, Rodriguez M. Biphasic and regionally-restricted chemokine expression in nervous system in the Theiler's virus model of multiple sclerosis. J Neurovirol 2000; 6:44-52.
20. Merril JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993; 151: 2132-41.
21. Bo L, Wesselingh DT, Mork S, Choi S, Kong PA, Hanley D, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36: 778-86.
22. De Groot CJA, Ruuls SR, Theeuwes JWM, Dijkstra CD, Vandervalk P. Immunocytochemical characterization of the expression of the inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997; 56: 10-20.
23. Oleszak EL, Katsetos CD, Kuzmak J, Varadhachary A. Inducible nitric oxide synthase in Theiler's murine encephalomyelitis virus infection. J Virol 1997; 71: 3228-35.
24. Cross AH, Misko TP, Lin RF, Hickey WF, Troter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL/J mice. J Clin Invest 1994; 63: 16270.
25. Rose JW, Hill KE, Wada Y, Jurtz CI, Tsunoda I, Fujinami RS, et al. Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infection. J Neuroimmunol 1998; 81: 82-9.
26. Okuda Y, Sakoda S, Fujimura H, Yanagihara T. Nitric oxide via an inducible isoform of nitric oxide synthase is a possible factor to eliminate inflammatory cells from the central nervous system of mice with experimental allergic encephalomyelitis. J Neuroimmunol 1995; 62: 103-12.
27. Okuda Y, Sakoda S, Fujimura H, Yanagihara T. Aminoguanidine, a selective inhibitor of the inducible nitric oxide synthase, has different effects on experimental allergic encephalomyelitis in the induction and progression phase. J Neuroimmunol 1998; 81: 201-10.
28. Rossi CP, Delcroix M, Huitinga I, et al. Role of macrophages during Theiler's virus infection. J Virol 1997; 71: 8592-601.
29. Rodríguez M, Leibowitz JL, Lampert PW. Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Ann Neurol 1983; 13: 426-33.
30. Qi Y, Dal Canto MC. Effect of Theiler's murine encephalomyelitis virus and cytokines on cultured oligodendrocytes and astrocytes. J Neurosci Res 1996; 45: 364-74.
31. Molina-Holgado F, Lledó A, Guaza C. Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997; 8: 1929-33.
32. Molina-Holgado, E, Arévalo-Martín A, Ortiz S, Vela JM, Guaza C. Theiler's virus infection induces the expression of cyclooxygenase-2 in murine astrocytes: Inhibition by the anti-inflammatory cytokines interleukin-4 and interleukin-10. Neurosci Let 2002; 324: 327.
33. Molina-Holgado E, Arévalo-Marín A, Castrillo A, Boscá L, Vela JM, Guaza C. Interleukin-4 and interleukin-10 modulate nuclear factors kB activity and nitric oxide synthase-2 expression in Theiler's virus-infected brain astrocytes. J Neurochem 2002; 81: 1242.
34. Tsunoda I, Kurtz CIB, Fujinami RS. Apoptosis in acute and chronic central nervous system disease induced by Theiler's murine encephalomyelitis virus. Virology 1997; 228: 388-9.
35. Begolka WS, Vanderlught CL, Rahbe SM, Miller SD. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998; 161: 4437-46.
36. Palma JP, Park SH, Kim BS. Treatment with lipopolysaccharide enhances the pathogenicity of a low-pathogenic variant of Theiler's murine encephalomyelitis virus. J Neurosci Res 1996; 45: 776-85.
37. Betelli E, Prabhu-Das M, Howard ED, Weiner HL, Sober RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice. J Immunol 1998; 161: 3299-306.
38. Hill KE, Pigmans M, Fujinami RS, Rose JW. Gender variations in early Theiler's virus induced demyelinating disease: Differential susceptibility and effects of IL-4, IL-10 and combined IL-4 with IL-10. J Neuroimmunol 1998; 85: 44-51.
39. Miller DH, Grossman RI, Reingold SC, Mc Farland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121: 3-24.
40. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
41. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
42. McGavem DB, Murray PD, Rivera-Quiñones C, Schmelzer JD, Low PA, Rodriguez, M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000; 123: 519-31.
43. Ure D, Rodriguez M. Extensive injury of descending neurons demonstrated by retrograde labeling in a virus-induced murine model of chronic inflammatory demyelination. J Neuropathol Exp Neurol 2000; 59: 664-78.
44. Griffiths I, Klugmann M, Anderson T, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998; 280: 1610-3.
45. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67-70.
46. Friedmann A, Frankel G, Lorch Y, Steimann L. Monoclonal antiI-A antibody reverses chronic paralysis and demyelination in Theiler's virus infected mice: Critical importance of timing treatment. J Virol 1987; 61: 898-902.
47. Rodriguez M, Pavelko KD, Mc Kinney CW, Leibowitz JL. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 1994; 153: 3811-21.
48. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1997; 83: 113-8.
49. Drescher KM, Murray PD, Lin X, Carlino JA, Rodríguez M. TGF-b2 reduces demyelination, virus antigen expression and macrophage recruitment in a viral model of multiple sclerosis. J Immunol 2000; 164: 3207-13.
50. Njenga MK, Coenen MJ, Decuir N, Yeh H, Rodríguez M. Short-term treatment with interferon-α/β promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. J Neurosci Res 2000; 59: 661-70.
51. Warrington AE, Asakura K, Bieber AJ, Bojolbub C, Van Keulen V, Kaveru SV, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. PNAS USA 2000; 97: 6820-5.